



**PB 49 of 2024**

# **National Health (Minimum Stockholding) Amendment Determination (No. 4) 2024**

---

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 29 April 2024

Nikolai Tsyganov  
Assistant Secretary  
Pricing and PBS Policy Branch  
Technology Assessment and Access Division  
Department of Health and Aged Care

---



---

## Contents

1 Name .....	1
2 Commencement.....	1
3 Authority .....	1
4 Schedules.....	1
<b>Schedule 1—Amendments commencing 1 May 2024</b>	<b>2</b>
<i>National Health (Minimum Stockholding) Determination 2023</i>	2
<b>Schedule 2—Amendments commencing 1 October 2024</b>	<b>7</b>
<i>National Health (Minimum Stockholding) Determination 2023</i>	7



---

## 1 Name

- (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No.4) 2024*.
- (2) This instrument may also be cited as PB 49 of 2024.

## 2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	1 May 2024.	1 May 2024
2. Schedule 1	1 May 2024.	1 May 2024
3. Schedule 2	1 October 2024.	1 October 2024

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

## 3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

## 4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

---

# Schedule 1—Amendments commencing 1 May 2024

## *National Health (Minimum Stockholding) Determination 2023*

### 1 Schedule 1 (table)

Before:

Acarbose	Tablet 100 mg	Oral	Acarbose Viatris	4 months stock by reference to usual demand of both Acarbose Viatris and Acarbose Mylan added together
----------	---------------	------	------------------	--

insert:

Acamprosate	Tablet (enteric coated) containing acamprosate calcium 333 mg	Oral	Acamprosate Viatris	after 30 July 2024—4 months stock by reference to usual demand of both Acamprosate Viatris and Acamprosate Mylan added together
-------------	---	------	---------------------	---

### 2 Schedule 1 (table)

After:

Acarbose	Tablet 100 mg	Oral	GLYBOSAY	2 months stock by reference to usual demand
----------	---------------	------	----------	---

insert:

Acarbose	Tablet 50 mg	Oral	Acarbose Viatris	after 30 July 2024—4 months stock by reference to usual demand of both Acarbose Viatris and Acarbose Mylan added together
----------	--------------	------	------------------	---

### 3 Schedule 1 (table)

Omit:

Amlodipine	Tablet 10 mg (as besilate)	Oral	Norvapine	between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand
Amlodipine	Tablet 5 mg (as besilate)	Oral	Norvapine	between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand

#### 4 Schedule 1 (table)

After:				
Carmellose with glycerin	Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL	Application to the Eye	Optive	4 months stock by reference to usual PBS demand
insert:				
Cefazolin	Powder for injection 2 g (as sodium)	Injection	Cephazolin Viatris	after 30 July 2024—6 months stock by reference to usual demand of both Cephazolin Viatris and Cephazolin Alphapharm added together
Cefazolin	Powder for injection 500 mg (as sodium)	Injection	Cefazolin-AFT	between 1 May 2024 and 30 July 2024—0 months stock by reference to usual demand
Cefepime	Powder for injection 1 g (as hydrochloride)	Injection	Omegapharm Pty Ltd	between 1 May 2024 and 31 May 2024—0 months stock by reference to usual demand
Cefepime	Powder for injection 2 g (as hydrochloride)	Injection	Omegapharm Pty Ltd	between 1 May 2024 and 31 May 2024—0 months stock by reference to usual demand
Ceftriaxone	Powder for injection 1 g (as sodium)	Injection	Ceftriaxone Viatris	after 31 May 2024—6 months stock by reference to usual demand of both Ceftriaxone Viatris and Ceftriaxone Alphapharm added together

#### 5 Schedule 1 (table)

Omit:				
Diclofenac	Tablet (enteric coated) containing diclofenac sodium 25 mg	Oral	Diclofenac Sandoz	between 1 November 2023 and 30 April 2024—4 months stock by reference to usual demand
Diclofenac	Tablet (enteric coated) containing diclofenac sodium 25 mg	Oral	Fenac 25	between 1 March 2024 and 31 March 2024—0 months stock by reference to usual demand

Diclofenac	Tablet (enteric coated) containing diclofenac sodium 50 mg	Oral	Diclofenac Sandoz	between 1 November 2023 and 30 April 2024—4 months stock by reference to usual demand
Diltiazem	Tablet containing diltiazem hydrochloride 60 mg	Oral	Diltiazem AN	Between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

## 6 Schedule 1 (table)

Omit:

Macrogol 3350	Oral liquid 13.125 g in 25 mL with electrolytes, 500 mL	Oral	Movicol Liquid	between 1 January 2024 and 30 April 2024—0 months stock by reference to usual demand
---------------	---	------	----------------	--

## 7 Schedule 1 (table)

Omit:

Metoprolol	Tablet containing metoprolol tartrate 50 mg	Oral	Metrol 50	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand
------------	---	------	-----------	--

## 8 Schedule 1 (table)

After:

Milk protein and fat formula with vitamins and minerals -- carbohydrate free	Oral powder 225 g (Carbohydrate Free Mixture)	Oral	Carbohydrate Free Mixture	6 months stock by reference to usual PBS demand
--	---	------	---------------------------	---

insert:

Mitozantrone	Injection 25 mg (as hydrochloride) in 12.5 mL	Injection	Onkotrone	between 1 May 2024 and 30 July 2024—0 months stock by reference to usual demand
--------------	---	-----------	-----------	---

## 9 Schedule 1 (table)

Omit:

Pregabalin	Capsule 150 mg	Oral	LYPRALIN	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
------------	----------------	------	----------	--



---

### 10 Schedule 1 (table)

Omit:

Pregabalin	Capsule 75 mg	Oral	LYPRALIN	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
------------	---------------	------	----------	--

### 11 Schedule 1 (table)

Omit:

Risperidone	Tablet 4 mg	Oral	Risperidone generichealth	between 1 February 2024 and 30 April 2024—0 months stock by reference to usual demand
-------------	-------------	------	------------------------------	---

### 12 Schedule 1 (table)

After:

Roxithromycin	Tablet 150 mg	Oral	APX-Roxithromycin	4 months stock by reference to usual demand
---------------	---------------	------	-------------------	---

insert:

Roxithromycin	Tablet 150 mg	Oral	Roximycin	between 1 May 2024 and 30 June 2024—0 months stock by reference to usual demand
---------------	---------------	------	-----------	---

### 13 Schedule 1 (table)

After:

Roxithromycin	Tablet 300 mg	Oral	APX-Roxithromycin	(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—5 months stock by reference to usual demand
---------------	---------------	------	-------------------	--

insert:

Roxithromycin	Tablet 300 mg	Oral	Roximycin	between 1 May 2024 and 30 June 2024—0 months stock by reference to usual demand
---------------	---------------	------	-----------	---

---

**14 Schedule 1 (table)**

Omit:

Topiramate	Tablet 100 mg	Oral	Topamax	between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand
------------	---------------	------	---------	--

**15 Schedule 1 (table)**

Omit:

Topiramate	Tablet 200 mg	Oral	Topamax	between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand
------------	---------------	------	---------	--

**16 Schedule 1 (table)**

Omit:

Topiramate	Tablet 25 mg	Oral	Topamax	between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand
------------	--------------	------	---------	--

**17 Schedule 1 (table)**

Omit:

Topiramate	Tablet 50 mg	Oral	Topamax	between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand
------------	--------------	------	---------	--

---

## Schedule 2—Amendments commencing 1 October 2024

### *National Health (Minimum Stockholding) Determination 2023*

#### 1 Schedule 1 (table)

After:

Allopurinol	Tablet 300 mg	Oral	Zyloprim	4 months stock by reference to usual demand
-------------	---------------	------	----------	---

insert:

Amino acid formula with vitamins and minerals without lysine and low in tryptophan	Sachets containing oral powder 24 g, 30 (GA gel)	Oral	GA gel	6 months stock by reference to usual PBS demand
--	--	------	--------	---

#### 2 Schedule 1 (table)

After:

Bosentan	Tablet 62.5 mg (as monohydrate)	Oral	Tracleer	between 1 April 2024 and 31 May 2024— 0 months stock by reference to usual demand
----------	---------------------------------	------	----------	--

insert:

Budesonide	Nebuliser suspension 500 micrograms in 2 mL single dose units, 30	Inhalation	Pulmicort Respules	6 months stock by reference to usual PBS demand
------------	---	------------	--------------------	---

---

Budesonide	Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses	Inhalation by Mouth	Pulmicort Turbuhaler	6 months stock by reference to usual PBS demand
------------	---	---------------------	----------------------	---

#### 3 Schedule 1 (table)

After:

Furosemide	Oral solution 10 mg per mL, 30 mL	Oral	Lasix	4 months stock by reference to usual PBS demand
------------	-----------------------------------	------	-------	---

insert:

Fusidic acid	Tablet containing sodium fusidate 250 mg	Oral	Fucidin	6 months stock by reference to usual PBS demand
--------------	--	------	---------	---

---

#### 4 Schedule 1 (table)

After:

Insect allergen extract-yellow jacket venom	Injection set containing 550 micrograms with diluent	Injection	Hymenoptera Yellow Jacket Venom	after 30 November 2023—6 months stock by reference to usual PBS demand
---	--	-----------	---------------------------------	--

insert:

Isoleucine with carbohydrate	Sachets of oral powder 4 g containing 1 g isoleucine, 30 (Isoleucine 1000)	Oral	Isoleucine 1000	6 months stock by reference to usual PBS demand
------------------------------	--	------	-----------------	---

---

Isoleucine with carbohydrate	Sachets of oral powder 4 g containing 50 mg isoleucine, 30 (Isoleucine 50)	Oral	Isoleucine 50	6 months stock by reference to usual PBS demand
------------------------------	--	------	---------------	---

#### 5 Schedule 1 (table)

After:

Prochlorperazine	Injection containing prochlorperazine mesilate 12.5 mg in 1 mL	Injection	Stemetil	6 months stock by reference to usual PBS demand
------------------	--	-----------	----------	---

insert:

Promethazine	Injection containing promethazine hydrochloride 50 mg in 2 mL	Injection	DBL Promethazine Hydrochloride	6 months stock by reference to usual PBS demand
--------------	---	-----------	--------------------------------	---